Expression of c‐erbB‐2 oncoprotein in human thyroid tumours

Utrilla, José C.; Martín-Lacave, Inés; Martín, María; Fernández-Santos, José M.; Galera-Davidson, H

doi:10.1046/j.1365-2559.1999.00563.x

Cited by 26 publications

(17 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In some of our cases, however, we observed variable cytoplasmic expression of HER-2. The relevance of this finding, as in other tumors, is currently unknown [12,13,15,[33][34][35]. Our findings indicate that potential targeted therapy of ATC with trastuzumab (Herceptin; Genetech Inc., South San Francisco, CA) may be considered individually.…”

Section: Discussionmentioning

confidence: 57%

“…Studies of HER-2 in thyroid tumors have reported an association between overexpression and aggressive behavior in differentiated thyroid carcinomas [12][13][14]. Interestingly, low or loss of HER-2 expression has been reported in undifferentiated thyroid tumors, suggesting that its downregulation plays a role in the biologic progression of some of these tumors [15,16].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification

et al. 2008

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 57%

Section: Introductionmentioning

confidence: 99%

Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification

et al. 2008

View full text Add to dashboard Cite

“…Utrilla et al (20) investigated 67 thyroid tumors (10 follicular adenomas, 11 follicular carcinomas, 3 anaplastic carcinomas, 25 papillary carcinomas, 18 medullary carcinomas and 16 metastases) for HER-2 expression by IHC using an antigen aretrieval method for paraffin-embedded material and a specific polyclonal antibody against the intracytoplasmic part of the HER-2 oncoprotein. No expression of this oncoprotein was detected in follicular adenomas, follicular carcinomas and anaplastic carcinomas; however, 52% of the papillary carcinomas (some membranous staining, but mostly diffuse cytoplasmic staining patterns) and all the medullary carcinomas (granular cytoplasmic staining pattern) were immunopositive.…”

Section: Discussionmentioning

confidence: 99%

Lack of HER-2 gene amplification and association with pathological and clinical characteristics of differentiated thyroid cancer

Mdah

Mzalbat

Gilbey

et al. 2014

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Human epidermal growth factor receptor 2 (HER-2) is a well recognized prognostic and predictive factor in breast cancer. However, the role of HER-2 in thyroid cancer remains controversial. The aim of this study was to evaluate HER-2 expression in differentiated thyroid cancer (DTC) and determine whether there is an association with other clinical and pathological characteristics. A total of 69 patients with DTC were investigated, 58 of whom had papillary and 11 follicular carcinomas. HER-2 was detected by immunohistochemical examination on sections from formalin-fixed, paraffin-embedded tumor tissues. Tumors with HER-2 expression classed as +1 and +2 were retested with chromogenic in situ hybridization. Clinicopathological data were retrieved from the hospital records of the patients. HER-2 overexpression was found in 4 (6.9%) of the 58 patients with papillary carcinoma, whereas there was no HER-2 overexpression in any of the 11 cases of follicular carcinoma. There was no association of HER-2 expression with tumor size, pathological grade and cervical lymph node metastasis. In conclusion, there were no HER-2 positive cases of follicular carcinoma and the incidence of HER-2 overexpression in papillary carcinoma was very low. Thus, HER-2 cannot be used routinely as a prognostic or predictive factor in DTC. The expression of other epidermal growth factor receptors in DTC merits further investigation.

show abstract

“…As there is no striking difference between the prognosis of patients with follicular carcinoma and papillary carcinoma, regulation of some other type than caveolin-1 must operate for signal transduction in follicular carcinomas. A previous study observed that c-erbB-2 oncoprotein was expressed in more than 50% of papillary carcinomas but not in follicular carcinomas or undifferentiated carcinomas (Utrilla et al, 1999). The difference in the status of these proteins in papillary and follicular carcinomas reflects the difference of entities between these two types of carcinoma.…”

Section: Molecular and Cellular Pathologymentioning

confidence: 90%

Caveolin-1 overexpression is an early event in the progression of papillary carcinoma of the thyroid

et al. 2002

View full text Add to dashboard Cite

Caveolin-1 is a major structural component of caveolae, which are plasma membrane microdomains implicated in the regulation of intracellular signalling pathways. Previous in vitro and in vivo studies on the function of caveolin-1 in carcinoma showed controversial results, indicating that the physiological role of caveolin-1 varies according to the origin of carcinoma. In this study, we investigated caveolin-1 expression in thyroid neoplasms by means of immunohistochemistry using a rabbit polyclonal antibody against caveolin-1. Normal follicular cells did not express caveolin-1. In papillary carcinoma, caveolin-1 expression was observed in high incidence, and especially in microcancer (less than 1.0 cm in diameter), caveolin-1 was positive in all cases except one. In undifferentiated (anaplastic) carcinoma, its incidence was significantly reduced. On the other hand, all cases of follicular carcinoma and adenoma were classified as negative for caveolin-1. These results suggest that caveolin-1 may play a role predominantly in the early phase of papillary carcinoma, whereas it has little influence on follicular tumours.

show abstract

Expression of c‐erbB‐2 oncoprotein in human thyroid tumours

Cited by 26 publications

References 19 publications

Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification

Growth factor receptors expression in anaplastic thyroid carcinoma: potential markers for therapeutic stratification

Lack of HER-2 gene amplification and association with pathological and clinical characteristics of differentiated thyroid cancer

Caveolin-1 overexpression is an early event in the progression of papillary carcinoma of the thyroid

Contact Info

Product

Resources

About